TOL-463
Phase 2Small molecule
TOL-463 is one of 25 small molecule programs targeting Vaginitis. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
65 competitors in Bacterial Vaginosis
#DrugCompanyPhaseTrials
1Acanya
PfizerApproved
Mycostatin
GGood Molecules, LLC
Approved
N-Acetyl Cyteien
SStanford University
Approved
Lactobacillus Acidophilus
UUniversiteit Antwerpen
Approved
Tindamax
MMission Pharmacal
Phase 3
Conventional
PPopulation Health Research Institute
Phase 3
Lactoferrin
UUniversità degli Studi di Ferrara
Phase 3
Lactoserum
SanofiApproved
Longidaza
NNPO Petrovax
Approved
Xifaxan
SSalix
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Bacterial Vaginosis1 trial
Suppression Of Bacterial Vaginosis (BV) [SUBVert]
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03930745·81 enrolled
Unspecified1 trial
Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01812889·26 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TOL-463. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TToltec Pharmaceuticals, LLC